started · updated
Evotec selected by Vertex Pharmaceuticals for povetacicept production
Evotec has been selected by Vertex Pharmaceuticals for the commercial manufacturing of povetacicept. This development follows the announcement of Evotec's preliminary nine-month financial results, which exceeded market expectations for both revenue and earnings.
In response to these updates, Evotec's share price rose by 4.0 percent. The company has confirmed its revenue forecast for 2026 and adjusted its expectations regarding adjusted EBITDA. The manufacturing project involves industrial scaling and quality assurance processes, and it is noted that the program is being pursued in coordination with the US Department of Defense.